Slingshot members are tracking this event:
Ignyta (RXDX) Secures Exclusive Global License to Lilly's (LLY) Oral Cancer Drug Candidate Taladegib for ~$53 Million plus an equity investment of $30mm in RXDX
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Nov 08, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Taladegib, Oral Cancer, Licensing